Literature DB >> 20056899

Variations of inflammatory mediators and alpha1-antitrypsin levels after lung volume reduction surgery for emphysema.

Davide Mineo1, Vincenzo Ambrogi, Maria Elena Cufari, Stefano Gambardella, Laura Pignotti, Eugenio Pompeo, Tommaso Claudio Mineo.   

Abstract

RATIONALE: In emphysema, chronic inflammation, including protease-antiprotease imbalance, is responsible for declining pulmonary function and progressive cachexia.
OBJECTIVES: To evaluate variations of inflammatory mediators and alpha(1)-antitrypsin levels after lung volume reduction surgery (LVRS) compared with respiratory rehabilitation.
METHODS: A total of 28 patients with moderate to severe emphysema, who underwent video-assisted thoracoscopic LVRS, were compared with 26 similar patients, who refused operation and followed a standardized rehabilitation program, and to a matched healthy group. Respiratory function, body composition, circulating inflammatory mediators, and alpha(1)-antitrypsin levels were evaluated before and 12 months after treatment. Gene expression levels of inflammatory mediators and protease-antiprotease were assessed in emphysematous specimens from 17 operated patients by matching to normal tissue from resection margins.
MEASUREMENTS AND MAIN RESULTS: Significant improvements were only obtained after surgery in respiratory function (FEV(1), +25.2%, P < 0.0001; residual volume [RV], -19.5%, P < 0.0001; diffusing lung capacity for carbon monoxide, +3.3%, P < 0.05) and body composition (fat-free mass, +6.5%, P < 0.01; fat mass, +11.9%, P < 0.01), with decrement of circulating inflammatory mediators (TNF-alpha, -22.2%, P < 0.001; IL-6, -24.5%, P < 0.001; IL-8, -20.0%, P < 0.001) and increment of antiprotease levels (alpha(1)-antitrypsin, +27.0%, P < 0.001). Supportive gene expression analysis demonstrated active inflammation and protease hyperactivity in the resected emphysematous tissue. Reduction of TNF-alpha and IL-6 and increment of alpha(1)-antitrypsin levels significantly correlated with reduction of RV (P = 0.03, P = 0.009, and P = 0.001, respectively), and partially with increment of fat-free mass (P = 0.03, P = 0.02, and P = 0.09, respectively).
CONCLUSIONS: LVRS significantly reduced circulating inflammatory mediators and increased antiprotease levels over respiratory rehabilitation, also improving respiratory function and nutritional status. Correlations of inflammatory mediators and antiprotease levels with RV and, partly, with body composition suggest that elimination of inflammatory emphysematous tissue may explain clinical improvements after surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056899     DOI: 10.1164/rccm.200910-1476OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

1.  CX3CR1+ lung mononuclear phagocytes spatially confined to the interstitium produce TNF-α and IL-6 and promote cigarette smoke-induced emphysema.

Authors:  Zeyu Xiong; Adriana S Leme; Prabir Ray; Steven D Shapiro; Janet S Lee
Journal:  J Immunol       Date:  2011-01-28       Impact factor: 5.422

Review 2.  Alternatives to lung transplantation: lung volume reduction for COPD.

Authors:  Gerard J Criner
Journal:  Clin Chest Med       Date:  2011-06       Impact factor: 2.878

3.  Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency.

Authors:  Victor Kim; Dana M Kretschman; Alice L Sternberg; Malcolm M DeCamp; Gerard J Criner
Journal:  Am J Respir Crit Care Med       Date:  2012-08-09       Impact factor: 21.405

Review 4.  Update in chronic obstructive pulmonary disease in 2010.

Authors:  Meilan K Han
Journal:  Am J Respir Crit Care Med       Date:  2011-05-15       Impact factor: 21.405

Review 5.  The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery.

Authors:  Gerard J Criner; Francis Cordova; Alice L Sternberg; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

6.  Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial.

Authors:  Carolyn E Come; Miguel J Divo; Raúl San José Estépar; Frank C Sciurba; Gerard J Criner; Nathaniel Marchetti; Steven M Scharf; Zab Mosenifar; Barry J Make; Cesar A Keller; Omar A Minai; Fernando J Martinez; MeiLan K Han; John J Reilly; Bartolome R Celli; George R Washko
Journal:  Respir Med       Date:  2011-08-16       Impact factor: 3.415

7.  Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease.

Authors:  Carlos H Martinez; Ya-Hong Chen; Phillip M Westgate; Lyrica X Liu; Susan Murray; Jeffrey L Curtis; Barry J Make; Ella A Kazerooni; David A Lynch; Nathaniel Marchetti; George R Washko; Fernando J Martinez; Meilan K Han
Journal:  Thorax       Date:  2012-05       Impact factor: 9.139

Review 8.  Heterogeneity of lung mononuclear phagocytes in chronic obstructive pulmonary disease.

Authors:  Janet S Lee
Journal:  J Innate Immun       Date:  2012-05-03       Impact factor: 7.349

9.  Compensatory lung growth after bilobectomy in emphysematous rats.

Authors:  Francine Maria Almeida; Beatriz Mangueira Saraiva-Romanholo; Rodolfo Paula Vieira; Henrique Takachi Moriya; Ana Paula Ligeiro-de-Oliveira; Fernanda Dtqs Lopes; Hugo C Castro-Faria-Neto; Thais Mauad; Milton Arruda Martins; Rogerio Pazetti
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

10.  Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.

Authors:  Victor Pinto-Plata; Ciro Casanova; Hana Müllerova; Juan P de Torres; Henneth Corado; Nerea Varo; Elizabeth Cordoba; Salah Zeineldine; Hildegarde Paz; Rebeca Baz; Miguel Divo; Felipe Cortopassi; Bartolome R Celli
Journal:  Respir Res       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.